伏立康唑治疗血液病合并侵袭性真菌感染23例

Voriconazole in the treatment of invasive fungal infection in hematologic patients:report of 23 cases

目的观察伏立康唑治疗血液病患者侵袭性真菌感染(IFI)的疗效和安全性。方法观察伏立康唑治疗血液病患者IFI的疗效和安全性。结果 23例患者中,治愈3例(13.1%),显效13例(56.5%),总有效率69.6%;进步1例(4.3%);无效6例。用药期间1例出现皮疹,1例出现血清转氨酶升高,1例出现胆红素升高,4例患者有轻度视觉异常。对症处理或停药后均缓解。结论伏立康唑是治疗血液病患者合并IFI患者的高效广谱抗真菌药物,其所致不良事件较少且患者大多能耐受。

Objective To observe the efficacy and safety of voriconazole for the treatment of invasive fungal infection （IFI） in patients with hematologic disease.Methods Twenty-three patients with hematologic disease complicated with IFI were treated with voriconazole-based therapy. The efficacy and adverse effect were evaluated.Results Good response was seen in 16 patients （69.6%）. Six patients （26.1%） showed complete response and 10 （43.5%） partial response. Elevated liver function test and bilirubin were reported in one patient each. Visual disturbance and skin rash were considered the main drug-related adverse events.Conclusions Voriconazole is an efficacious and well-tolerated antifungal agent in the treatment of IFI in patients with hematologic disease.